摘要
目的探讨利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效。方法根据随机数字表法将方便选取2017年1月—2018年1月该院诊治的90例2型糖尿病患者分成两组。对照组给予二甲双胍治疗,观察组则给予二甲双胍联合利拉鲁肽治疗。比较两组2型糖尿病治疗转归效果;血糖达到标准范围的时间;治疗前后患者血糖以及胰岛素敏感性、糖化血红蛋白、体重指数;用药安全特点。结果观察组2型糖尿病治疗转归效果44例(97.78%)高于对照组(χ2=13.520,P<0.05);观察组血糖达到标准范围的时间(9.11±1.41)d优于对照组(13.42±2.25)d(t=8.132,P<0.05);治疗后观察组FBG、2 h PBG、HbA1c、胰岛素敏感性、体重指数(7.24±1.22)mmol/L、(9.12±2.21)mmol/L、(6.21±2.11)%、(-3.56±0.11)、(25.19±2.12)kg/m2优于对照组(t=5.833、8.422、5.144、7.062、6.442,P<0.05)。观察组用药安全特点2例(4.44%)和对照组3例(6.67%)差异无统计学意义(χ2=0.211 8,P>0.05)。结论二甲双胍联合利拉鲁肽治疗2型糖尿病的疗效确切,可有效改善血糖以及改善胰岛素敏感性,用药安全,值得推广应用。
Objective To investigate the efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus.Methods According to the random number table method,90 patients with type 2 diabetes from January 2017 to January 2018 were conveniently selected and divided into two groups.The control group was treated with metformin,and the observation group was given metformin plus liraglutide.The effect of treatment on type 2 diabetes was compared between the two groups; the time when blood glucose reached the standard range; the blood glucose and insulin sensitivity,glycosylated hemoglobin,body mass index before and after treatment.Results The outcome of treatment for type 2 diabetes in the observation group was 44 cases (97.78%) higher than that of the control group(χ^2=13.520,P<0.05).The time to reach the standard range of blood glucose in the observation group was (9.11±1.41)d,which was better than the control group(13.42±2.25)d,(t=8.132,P<0.05); after treatment,FBG,2 hPBG,HbA1c,insulin sensitivity,body mass index (7.24±1.22)mmol/L,(9.12±2.21)mmol/L,(6.21±2.11)%,(-3.56±0.11),(25.19±2.12)kg/m^2 was better than the control group(t=5.833,8.422,5.144,7.062,6.442,P<0.05).There was no significant difference between the safety characteristics of the observation group 2 cases(4.44%) and the control group 3 cases(6.67%)(χ^2=0.211 8,P>0.05).Conclusion Metformin combined with liraglutide is effective in the treatment of type 2 diabetes.It can effectively improve blood glucose and improve insulin sensitivity.It is safe to use and worthy of popularization and application.
作者
杨锡泉
YANG Xi-quan(Department of Internal Medicine, Section One, Raoping County Hospital, Chaozhou, Guangdong Province, 515700 China)
出处
《中外医疗》
2018年第35期78-80,共3页
China & Foreign Medical Treatment
